66314-77-0Relevant articles and documents
An N-Fluorinated Imide for Practical Catalytic Imidations
Adachi, Akiya,Aikawa, Kohsuke,Hashimoto, Takuya,Ishibashi, Yuichiro,Oe, Yuno,Okazoe, Takashi,Tanaka, Airi,Yoshida, Ryuhei
supporting information, (2022/02/10)
Catalytic imidation using NFSI as the nitrogen source has become an emerging tool for oxidative carbon-nitrogen bond formation. However, the less than ideal benzenesulfonimide moiety is incorporated into products, severely detracting its synthetic value.
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors
Wang, Yihan,Shakespeare, William C.,Huang, Wei-Sheng,Sundaramoorthi, Raji,Lentini, Scott,Das, Sasmita,Liu, Shuangying,Banda, Geeta,Wen, David,Zhu, Xiaotian,Xu, Qihong,Keats, Jeffrey,Wang, Frank,Wardwell, Scott,Ning, Yaoyu,Snodgrass, Joseph T.,Broudy, Mark I.,Russian, Karin,Dalgarno, David,Clackson, Tim,Sawyer, Tomi K.
scheme or table, p. 4907 - 4912 (2009/05/30)
Novel N9-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N9 on the purine core which projects hydrophobic substituents into the sele
Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
-
, (2008/06/13)
The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.